This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sanofi Celebrates 50th Anniversary Of France - China Relations

PARIS, Jan. 27, 2014 (GLOBE NEWSWIRE) -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today its participation in the commemoration of the 50 th anniversary of diplomatic relations between France and the People's Republic of China. In supporting the celebration, Sanofi affirms its commitment to economic development and public health in China.

"As one of the first multinational pharmaceutical companies to operate in China, Sanofi has continually provided innovative healthcare solutions for patients, expanding in pace with the country's development," said Christopher A. Viehbacher, Chief Executive Officer, Sanofi. "Our expanding portfolio of medicines and vaccines allows us to contribute to important public health issues in China, such as chronic disease management, prevention and food safety."

As one of the commemoration's major sponsors, Sanofi will participate in scientific events throughout the year in France and China, which will include Chinese students from select academic institutions in France. Sanofi also plans to participate in the "Better Healthcare" conference in Beijing with "Club Santé Chine", an initiative by the French government to help small and medium enterprises export healthcare products.

China is a showcase for Sanofi's collaborative approach, with many research and development agreements signed in the past six years, including in the areas of cancer, stem cells, diabetes and aging diseases. Sanofi partners include Shanghai Institutes for Biological Sciences, the Tianjin Institute of Hematology and Peking University. In recognition of the richness of China's research ecosystem, Sanofi settled management of its Asia-Pacific research and development activities in China in 2011.

About Sanofi in China Present in China since 1982, Sanofi is committed to the treatment of chronic diseases, including through programs on diabetes, cardiovascular diseases and rare diseases. The Group has 11 regional offices and seven factories producing medicines, vaccines, animal health and consumer health products. As a global leader in consumer healthcare, Sanofi signed a joint venture with Minsheng in 2010 and acquired BMP Sunstone in 2011. Sanofi generated € 1.2 billion in revenues in China in 2012, and employs 8,500 people.

About Sanofi Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Relations Presse Relations Investisseurs
Laurence Bollack Sébastien Martel
Tel +33 (1) 53 77 46 46 Tel +33 (1) 53 77 45 45

PDF Version


Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.19 0.18%
FB $99.50 -4.40%
GOOG $670.00 -2.00%
TSLA $148.78 -8.50%
YHOO $26.69 -4.60%


Chart of I:DJI
DOW 15,878.12 -326.85 -2.02%
S&P 500 1,845.83 -34.22 -1.82%
NASDAQ 4,266.6530 -96.4910 -2.21%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs